Lixisenatide Doesn't Affect Cardiovascular Risk in T2DM

Share this content:
Lixisenatide Doesn't Affect Cardiovascular Risk in T2DM
Lixisenatide Doesn't Affect Cardiovascular Risk in T2DM

THURSDAY, Dec. 3, 2015 (HealthDay News) -- The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according to a study published in the Dec. 3 issue of the New England Journal of Medicine.

Marc A. Pfeffer, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues randomized patients with type 2 diabetes who had had myocardial infarction or who had been hospitalized for unstable angina within the prior 180 days to lixisenatide or placebo. A total of 6,068 patients were randomized and followed for a median of 25 months.

The researchers found that a primary end point event (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) occurred in 13.4 and 13.2 percent of the lixisenatide and placebo groups, respectively (hazard ratio, 1.02; 95 percent confidence interval, 0.89 to 1.17), demonstrating noninferiority (P < 0.001) but not superiority (P = 0.81). No significant between-group differences were seen in the rate of hospitalization for heart failure (hazard ratio, 0.96; 95 percent confidence interval, 0.75 to 1.23) or death (hazard ratio, 0.94; 95 percent confidence interval, 0.78 to 1.13).

"The neutral cardiovascular profile associated with lixisenatide will inform physicians' and patients' decisions regarding the use of this agent as an adjunctive therapy to control the glycated hemoglobin level safely," the authors write.

The study was funded by Sanofi, the manufacturer of lixisenatide.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »